GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Postal Ballot. Further, the company has submitted the Exchange a copy of Srutinizers report along with voting results.
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
GlaxoSmithKline Pharmaceuticals completed its postal ballot (remote e-voting) from 9 March 2026 to 8 April 2026 for two ordinary resolutions: appointing Mr. Ronojit Biswas as a Director and as Whole-time Director & Chief Financial Officer. Both resolutions passed with overwhelming shareholder support. For the Director appointment, 99.69% of votes polled (14.19 crore shares) were in favour, with only 0.31% against. For the CFO/Whole-time Director appointment, 99.76% (14.20 crore shares) voted in favour and 0.24% against. The promoter group, holding 12.70 crore shares (75% stake), voted 100% in favour of both resolutions. Out of 1,26,273 shareholders on record date, about 84% of outstanding shares participated in voting.
Mr. Ronojit Biswas is now formally appointed as Director and CFO of the company. This is a routine corporate governance update with no material impact on the stock price; the near-unanimous approval reflects strong shareholder confidence in the appointment.